BRIEF—Tvardi Therapeutics gets financing for STAT3-driven diseases candidate TTI-101 program

Privately-held Texas, USA-based Tvardi Therapeutics has announced the completion of a $9 million Series A financing round.

The funding is expected to enable the completion of ongoing Phase I studies for Tvardi’s lead compound TTI-101 in solid tumor cancers and the completion of IND-enabling studies of a second product for use in non-cancer indications.

“We are pleased with strong support and enthusiasm from the investment community, as we focus on advancing our products through clinical development,” said Dr Ronald DePinho Tvardi’s co-founder and director, adding: “the societal and economic impact of STAT3-driven diseases is significant and the successful development of a safe and effective STAT3 inhibitor such as TTI-101 could transform the lives of millions of patients affected with these diseases.”